JP2021036841A - Improved method for producing hyaluronic acid - Google Patents
Improved method for producing hyaluronic acid Download PDFInfo
- Publication number
- JP2021036841A JP2021036841A JP2019162229A JP2019162229A JP2021036841A JP 2021036841 A JP2021036841 A JP 2021036841A JP 2019162229 A JP2019162229 A JP 2019162229A JP 2019162229 A JP2019162229 A JP 2019162229A JP 2021036841 A JP2021036841 A JP 2021036841A
- Authority
- JP
- Japan
- Prior art keywords
- hyaluronic acid
- culture
- medium
- microorganism
- sugar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims abstract description 41
- 229920002674 hyaluronan Polymers 0.000 title claims abstract description 41
- 229960003160 hyaluronic acid Drugs 0.000 title claims abstract description 41
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 13
- 235000000346 sugar Nutrition 0.000 claims abstract description 27
- 244000005700 microbiome Species 0.000 claims abstract description 25
- 241000194020 Streptococcus thermophilus Species 0.000 claims abstract description 22
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 21
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 21
- 239000008103 glucose Substances 0.000 claims abstract description 21
- 239000008101 lactose Substances 0.000 claims abstract description 21
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 18
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims abstract description 13
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 13
- 238000012258 culturing Methods 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims description 16
- 150000008163 sugars Chemical class 0.000 claims description 5
- 239000002609 medium Substances 0.000 description 30
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 14
- 229910052799 carbon Inorganic materials 0.000 description 14
- 241000894006 Bacteria Species 0.000 description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
- 229930006000 Sucrose Natural products 0.000 description 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 7
- 239000005720 sucrose Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 5
- 239000000306 component Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000005273 aeration Methods 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 241000194048 Streptococcus equi Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000120569 Streptococcus equi subsp. zooepidemicus Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 150000001868 cobalt Chemical class 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- QYDYPVFESGNLHU-UHFFFAOYSA-N elaidic acid methyl ester Natural products CCCCCCCCC=CCCCCCCCC(=O)OC QYDYPVFESGNLHU-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- 239000010699 lard oil Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- QYDYPVFESGNLHU-KHPPLWFESA-N methyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC QYDYPVFESGNLHU-KHPPLWFESA-N 0.000 description 1
- 229940073769 methyl oleate Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229910017464 nitrogen compound Inorganic materials 0.000 description 1
- 150000002830 nitrogen compounds Chemical class 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
本発明は、乳酸菌によるヒアルロン酸の改良された製造方法に関するものである。 The present invention relates to an improved method for producing hyaluronic acid by lactic acid bacteria.
ヒアルロン酸は、コンドロイチン硫酸やヘパリン等とともに高価なグルコサミノグルカンであり、哺乳動物の結合組織中に微量であるが広く分布し、また微生物も産生することが知られている。そして、これらから抽出、精製された高純度のヒアルロン酸は、高い保湿性、高粘性、創傷治癒性等の性質を有することから、その機能に着目して、化粧品配合素材、眼科手術の際の保護剤、関節炎治療剤等として広く使用されている。
また、近年では、食品分野においても、保健効果や機能性等、付加価値に対する消費者の関心が高まっており、ヒアルロン酸は、それが持つ機能性により種々の効果が期待できることから、食品素材の一つとしても注目されている。
Hyaluronic acid is an expensive glucosaminoglucan together with chondroitin sulfate and heparin, and is known to be widely distributed in the connective tissue of mammals in a trace amount and also to produce microorganisms. High-purity hyaluronic acid extracted and purified from these has properties such as high moisturizing property, high viscosity, and wound healing property. Therefore, paying attention to its function, it is used as a cosmetic compound material and during eye surgery. Widely used as a protective agent, a therapeutic agent for arthritis, etc.
In recent years, consumers have been paying more attention to added values such as health effects and functionality in the food field, and hyaluronic acid can be expected to have various effects depending on its functionality. It is also attracting attention as one.
従来、ヒアルロン酸の製造は、鶏冠、牛の関節もしくは鯨の軟骨からの抽出による工業的な製法で行われてきたが、生体内にはヒアルロン酸が微量にしか存在せず、しかも、組織中でタンパク質や他のムコ多糖類と複合体を形成しているため、当該タンパク質やムコ多糖との分離精製に複雑な工程を必要とするため大量に生産することは難しく、微生物を用いた培養法によるヒアルロン酸の製造方法が一般的に実施されている。 Conventionally, hyaluronic acid has been produced by an industrial method by extracting it from chicken crown, cow joint or whale cartilage, but hyaluronic acid is present in a very small amount in the living body and in the tissue. Since it forms a complex with proteins and other mucopolysaccharides, it is difficult to produce in large quantities because it requires complicated steps to separate and purify the proteins and mucopolysaccharides. The method for producing hyaluronic acid according to the above is generally practiced.
ヒアルロン酸を産生する微生物としては、ストレプトコッカス・ピオゲネス(Streptococcus pyogenes)、ストレプトコッカス・ズーエピデミカス(Streptococcus zooepidemicus)、ストレプトコッカス・エクイ(Streptococcus equi)、ストレプトコッカス・エクイシミリス(Streptococcus equisimilis)、ストレプトコッカス・ディスガラクティエ(Streptococcus dysgalactiae)等のストレプトコッカス属細菌が知られている。また、本出願人は、ストレプトコッカス・サーモフィルスYIT2084株(FERM BP−10879)を始めとするストレプトコッカス・サーモフィルス属微生物が優れたヒアルロン酸産生能を有することを見出している(特許文献1)。 Examples of hyaluronic acid-producing microorganisms include Streptococcus pyogenes, Streptococcus zooepidemicus, Streptococcus equi, Streptococcus equi, Streptococcus equicisim Streptococcus spp., Etc. are known. In addition, the applicant has found that Streptococcus thermophilus microorganisms such as Streptococcus thermophilus YIT2084 strain (FERM BP-10879) have excellent hyaluronic acid producing ability (Patent Document 1).
本発明は、ストレプトコッカス・サーモフィルス属微生物を用いたヒアルロン酸のより効率的な製造方法を提供することに関する。 The present invention relates to providing a more efficient method for producing hyaluronic acid using a microorganism of the genus Streptococcus thermophilus.
本発明者らは、ストレプトコッカス・サーモフィルス属微生物を用いてヒアルロン酸を製造する場合に、当該微生物を、糖類としてグルコース及びラクトースから選ばれる1種以上を含む培地で前培養し、本培養においては、当該前培養で使用した糖類とは異なる糖を含む培地で培養した場合に、ヒアルロン酸の生産量が向上することを見出した。 When producing hyaluronic acid using a microorganism of the genus Streptococcus thermophilus, the present inventors preculture the microorganism in a medium containing one or more selected from glucose and lactose as saccharides, and in the main culture, the microorganism is precultured. , It was found that the production amount of hyaluronic acid is improved when the culture medium contains a sugar different from the sugar used in the preculture.
すなわち、本発明は以下の(1)〜(4)に係るものである。
(1)下記の工程;
a)ストレプトコッカス・サーモフィルス属微生物を、糖類としてグルコース及びラクトースから選ばれる1種以上を含む培地で、前培養する工程、
b)前記工程で前培養した微生物を、糖類として当該前培養で用いた糖とは異なる糖を含む培地に接種し、培養する工程、
を含むヒアルロン酸の製造方法。
(2)a工程における培地が糖類としてラクトースを含み、b工程における培地が糖類としてグルコースを含む、(1)の方法。
(3)a工程における培地が糖類としてグルコースを含み、b工程における培地が糖類としてラクトースを含む、(1)の方法。
(4)ストレプトコッカス・サーモフィルス属微生物がストレプトコッカス・サーモフィルスYIT2084株(FERM BP−10879)である(1)〜(3)のいずれかの方法。
That is, the present invention relates to the following (1) to (4).
(1) The following process;
a) A step of pre-culturing a Streptococcus thermophilus microorganism in a medium containing one or more selected from glucose and lactose as sugars.
b) A step of inoculating the microorganism pre-cultured in the above step into a medium containing a sugar different from the sugar used in the pre-culture as a sugar and culturing the mixture.
A method for producing hyaluronic acid, including.
(2) The method of (1), wherein the medium in step a contains lactose as a saccharide, and the medium in step b contains glucose as a saccharide.
(3) The method of (1), wherein the medium in step a contains glucose as a saccharide, and the medium in step b contains lactose as a saccharide.
(4) The method according to any one of (1) to (3), wherein the Streptococcus thermophilus microorganism is Streptococcus thermophilus YIT2084 strain (FERM BP-10879).
本発明の方法によれば、医薬品、化粧品、飲食品等へ配合可能なヒアルロン酸を効率よく安価かつ簡便に製造することができる。 According to the method of the present invention, hyaluronic acid that can be blended in pharmaceuticals, cosmetics, foods and drinks, etc. can be efficiently, inexpensively and easily produced.
本発明のヒアルロン酸の製造方法は、下記の工程a及びbを含むものである。
a)ストレプトコッカス・サーモフィルス属微生物を、糖類としてグルコース及びラクトースから選ばれる1種以上を含む培地で、前培養する工程、
b)前記工程で前培養した微生物を、糖類として当該前培養で用いた糖とは異なる糖を含む培地に接種し、培養する工程。
The method for producing hyaluronic acid of the present invention includes the following steps a and b.
a) A step of pre-culturing a Streptococcus thermophilus microorganism in a medium containing one or more selected from glucose and lactose as sugars.
b) A step of inoculating the microorganism pre-cultured in the above step into a medium containing a sugar different from the sugar used in the pre-culture as a sugar and culturing.
本発明の方法で使用するストレプトコッカス・サーモフィルス属微生物としては、ヒアルロン酸産生能を有するものであればよく、特に制限されることなく適用することが可能であり、具体的にはストレプトコッカス・サーモフィルスYIT2084株(FERM BP−10879)を挙げることができる。なお、ストレプトコッカス・サーモフィルスに属する前記微生物株は、独立行政法人特許微生物寄託センターに寄託されている。 The Streptococcus thermophilus microorganism used in the method of the present invention may be any microorganism having a hyaluronic acid-producing ability, and can be applied without particular limitation. Specifically, Streptococcus thermophilus. YIT2084 strain (FERM BP-10879) can be mentioned. The microbial strain belonging to Streptococcus thermophilus has been deposited at the Patent Microorganisms Depositary, Incorporated Administrative Agency.
1.工程a
本発明において、ストレプトコッカス・サーモフィルス属微生物を培養し、ヒアルロン酸を得るためには、保存菌体をまず少量の培地に接種して継代培養し、その後、大容積の培地へと順次接種を行いながらスケールアップを図ることが行われる。
本発明において、工程aは微生物菌体を順次継代しながら行なうスケールアップ途上の段階の培養(前培養)を意味し、工程bはヒアルロン酸を回収するために行われる最終ステップの培養(本培養)を意味する。
1. 1. Step a
In the present invention, in order to culture Streptococcus thermophilus microorganisms and obtain hyaluronic acid, the preserved cells are first inoculated into a small amount of medium and subcultured, and then sequentially inoculated into a large volume medium. Scale-up is done while doing it.
In the present invention, step a means culturing (preculture) in the process of scaling up while sequentially subculturing microbial cells, and step b is culturing in the final step (preculture) performed to recover hyaluronic acid. (Culture) means.
本発明において、前培養は、炭素源の一つである糖類としてグルコース及びラクトースから選ばれる1種以上を含む培地で行われるが、グルコース又はラクトースをそれぞれ単独で用いるのが好ましい。培地中の当該糖類の濃度は、好ましくは0.1g/L〜50g/Lであり、より好ましくは1g/L〜30g/Lであり、更に好ましくは10g/L〜20g/Lである。 In the present invention, the preculture is carried out in a medium containing at least one selected from glucose and lactose as a saccharide which is one of the carbon sources, but it is preferable to use glucose or lactose alone. The concentration of the saccharide in the medium is preferably 0.1 g / L to 50 g / L, more preferably 1 g / L to 30 g / L, and even more preferably 10 g / L to 20 g / L.
本発明の前培養は、糖類として前記の糖を用いる以外は、一般に乳酸菌の前培養に使用される培地成分を含有する培地で行うことができるが、工程bの培養へ接種する菌体をできるだけ増やす観点から、増殖能の高い栄養培地で培養するのが好ましい。
例えば、窒素源としては、肉エキス、カゼイン、ペプトン、酵母エキス、乾燥酵母、胚芽、大豆粉、尿素、アミノ酸、アンモニウム塩等の有機・無機窒素化合物を用いることができ、ナトリウム塩、カリウム塩、カルシウム塩、マグネシウム塩、リン酸塩、鉄塩、銅塩、亜鉛塩、コバルト塩等の無機塩類を必要に応じて適宜添加することができる。更に、ビオチン、ビタミンB1、シスチン、オレイン酸メチル、ラード油等の生育促進物質の他、シリコン油、界面活性剤等の消泡剤を添加することができる。
尚、炭素源としては、前記の糖類以外の油脂類等の有機炭素化合物を含んでいてもよいが、前記糖類のみを炭素源とするのが好ましい。
具体的には、例えば、後述の表1に示す、炭素源としてラクトース又はグルコースを含むILS培地等が挙げられる。
The pre-culture of the present invention can be carried out in a medium containing a medium component generally used for the pre-culture of lactic acid bacteria, except that the above-mentioned sugar is used as the sugar, but the cells to be inoculated into the culture in step b can be as much as possible. From the viewpoint of increasing, it is preferable to culture in a nutrient medium having high proliferative ability.
For example, as the nitrogen source, organic / inorganic nitrogen compounds such as meat extract, casein, peptone, yeast extract, dried yeast, germ, soybean flour, urea, amino acid, and ammonium salt can be used, and sodium salt, potassium salt, and the like can be used. Inorganic salts such as calcium salt, magnesium salt, phosphate, iron salt, copper salt, zinc salt and cobalt salt can be appropriately added as needed. Further, in addition to growth-promoting substances such as biotin, vitamin B1, cystine, methyl oleate, and lard oil, defoaming agents such as silicone oil and surfactant can be added.
The carbon source may contain an organic carbon compound such as oils and fats other than the above-mentioned saccharides, but it is preferable to use only the above-mentioned saccharides as a carbon source.
Specifically, for example, an ILS medium containing lactose or glucose as a carbon source shown in Table 1 described later can be mentioned.
一般的に菌を培地に接種した後、培養を開始して菌を増殖させる第1段目の前培養が行われ、次いで、この培養液を、次段階の前培養(第2段目)の培地へ接種して、同様に培養することができる。すなわち、前培養における培養は、本培養の液量に応じて、適宜繰り返して行われ、通常2段階以上、好ましくは2〜3段階行われる。また、前培養の液量は段数とともに増やすのが好ましい。本発明において、前培養で行われる培養(前培養が複数段階行われる場合は、そのうちの少なくとも1段階の任意の培養)を工程aという。前培養が複数段階行われる場合、工程aを連続的に又は断続的に複数回行ってもよく、少なくとも本培養の1段階前の前培養を工程aとすることが好ましく、複数回の前培養を全て工程aの繰り返しとして行うことがより好ましい。 Generally, after inoculating the bacterium into the medium, the first-stage preculture is performed in which the culture is started to grow the bacterium, and then this culture solution is used for the next-stage preculture (second stage). It can be inoculated into a medium and cultured in the same manner. That is, the culture in the pre-culture is appropriately repeated depending on the liquid volume of the main culture, and is usually carried out in two or more steps, preferably in two or three steps. Moreover, it is preferable to increase the amount of liquid in the preculture with the number of stages. In the present invention, the culture performed in the pre-culture (when the pre-culture is performed in a plurality of stages, at least one stage of the culture is arbitrary) is referred to as step a. When the pre-culture is performed in a plurality of stages, the step a may be continuously or intermittently performed a plurality of times, and it is preferable that the pre-culture one step before the main culture is the step a, and the pre-culture is performed a plurality of times. It is more preferable that all of the above steps are repeated in step a.
培養温度は、25〜42℃、好ましくは30〜40℃であり、培養時間は、12〜72時間、好ましくは24〜48時間である。培養形態としては、静置培養、振盪培養、攪拌培養等の何れでも良いが、通気なしの攪拌培養が好ましい。
また、培地のpHは6〜8程度に調整するのが好ましく、中性領域で行うことがより好ましい。
The culture temperature is 25 to 42 ° C., preferably 30 to 40 ° C., and the culture time is 12 to 72 hours, preferably 24 to 48 hours. The culture form may be any of static culture, shaking culture, stirring culture and the like, but stirring culture without aeration is preferable.
The pH of the medium is preferably adjusted to about 6 to 8, and more preferably in the neutral region.
2.工程b
本工程において、ストレプトコッカス・サーモフィルス属微生物の培養に用いる培地は、炭素源のうち、糖類として用いられる糖が、工程aで用いた糖とは異なるものを含む。ここで、糖としては、グルコース、フルクトース等の単糖類、ラクトース、スクロース、マルトース等の二糖類、オリゴ糖類等が挙げられるが、前培養において、糖類としてラクトースを用いた場合、本工程の培地にはラクトース以外の糖、例えばグルコース、スクロース等が用いられ、好ましくはグルコースが用いられる。また、前培養において、糖類としてグルコースを用いた場合は、本工程の培地にはグルコース以外の糖、例えばラクトース、スクロース等が用いられ、好ましくはラクトースが用いられる。
培地中の当該糖類の濃度は、好ましくは1g/L〜200g/Lであり、より好ましくは5g/L〜100g/Lであり、更に好ましくは10g/L〜50g/Lである。
2. Step b
In this step, the medium used for culturing the Streptococcus thermophilus microorganism contains a carbon source in which the sugar used as the saccharide is different from the sugar used in the step a. Here, examples of the sugar include monosaccharides such as glucose and fructose, disaccharides such as lactose, sucrose and maltose, oligosaccharides and the like. However, when lactose is used as the saccharide in the preculture, it is used as the medium in this step. For sugars other than lactose, for example, glucose, sucrose and the like are used, and glucose is preferably used. When glucose is used as the sugar in the preculture, sugars other than glucose, such as lactose and sucrose, are used as the medium in this step, and lactose is preferably used.
The concentration of the saccharide in the medium is preferably 1 g / L to 200 g / L, more preferably 5 g / L to 100 g / L, and even more preferably 10 g / L to 50 g / L.
炭素源以外の成分としては、通常の乳酸菌の培養に使用される成分を用いることができる。斯かる成分としては、リン酸一カリウム、リン酸二カリウム、硫酸マグネシウム、亜硫酸ソーダ、チオ硫酸ソーダ、リン酸アンモニウム等の無機塩類、ポリペプトン、酵母エキス、コーンスティープリカー等の有機栄養源の他、必要に応じて各種アミノ酸等が挙げられる。また、ヒアルロン酸の産生量を増加させる点から、大豆ペプチドを添加することもできる。 As a component other than the carbon source, a component used for culturing ordinary lactic acid bacteria can be used. Such components include inorganic salts such as monopotassium phosphate, dipotassium phosphate, magnesium sulfate, sodium sulfite, sodium thiosulfate, ammonium phosphate, and organic nutrient sources such as polypeptone, yeast extract, and corn steep liquor. Various amino acids and the like can be mentioned as needed. In addition, soybean peptide can be added from the viewpoint of increasing the amount of hyaluronic acid produced.
前培養したストレプトコッカス・サーモフィルス属微生物の本工程の培地への接種量は、特に限定されるものではないが、ヒアルロン酸の生産性の点から、本培養液の0.1〜5%、より好ましくは、0.5〜3%、更に好ましくは1〜2%である。
本工程における培養は、振盪培養、通気攪拌培養等の公知の方法から適宜選択して用いればよい。
培養温度は、25〜42℃、好ましくは30〜40℃が挙げられ、培養時間は、12〜72時間、好ましくは24〜48時間である。また、培養液のpHは、当該乳酸菌の発育と共に低下し、ヒアルロン酸の産生量に影響を与える場合があるため、苛性ソーダ、苛性カリ、アンモニア等の各種pH調整剤を用いておよそ6〜8、好ましくは6.5〜7.5に調整しておくことが好ましい。
The amount of the pre-cultured Streptococcus thermophilus microorganisms inoculated into the medium in this step is not particularly limited, but from the viewpoint of hyaluronic acid productivity, 0.1 to 5% of the main culture solution, It is preferably 0.5 to 3%, more preferably 1 to 2%.
The culture in this step may be appropriately selected from known methods such as shaking culture and aeration stirring culture.
The culture temperature is 25 to 42 ° C., preferably 30 to 40 ° C., and the culture time is 12 to 72 hours, preferably 24 to 48 hours. In addition, the pH of the culture solution decreases with the growth of the lactic acid bacterium and may affect the amount of hyaluronic acid produced. Therefore, about 6 to 8 is preferable using various pH adjusters such as caustic soda, caustic potash, and ammonia. Is preferably adjusted to 6.5-7.5.
培養終了後、ヒアルロン酸は、通常の多糖類の分離・採取方法に従って、培養液から分離・採取すればよい。例えば、培養液中の菌体などの不溶物をろ過または遠心分離により分別後、この溶液から、例えばエタノール等の溶媒沈殿剤を用いて精製ヒアルロン酸を分取することができる。 After completion of the culture, hyaluronic acid may be separated / collected from the culture solution according to a usual method for separating / collecting polysaccharides. For example, insoluble matter such as bacterial cells in the culture solution can be separated by filtration or centrifugation, and then purified hyaluronic acid can be separated from this solution using a solvent precipitant such as ethanol.
斯くして本発明の方法により得られるヒアルロン酸は、その平均分子量は、30万〜150万、さらに30万〜100万程度である。また、その分子量分布は、200万〜2万程度の範囲であり、その最大ピークは40〜50万あたりにある。 The hyaluronic acid thus obtained by the method of the present invention has an average molecular weight of about 300,000 to 1,500,000, and further about 300,000 to 1,000,000. The molecular weight distribution is in the range of about 2 million to 20,000, and the maximum peak is around 400,000 to 500,000.
本発明の方法で得られるヒアルロン酸は、従来と同様に、医薬品や化粧品等の形態で使用することができる他、ヨーグルト等の製造に利用できるストレプトコッカス・サーモフィルス属微生物が産生するものであるため、食品の形態として投与することも可能である。例えば、本発明の方法で得られるヒアルロン酸を美容や老化防止などの効果を訴求する医薬品や栄養補助食品等の形態で用いる場合であれば、カプセル剤、顆粒剤、錠剤、散剤等の固形製剤、或いはシロップ剤等の液状製剤として経口投与することができる。 The hyaluronic acid obtained by the method of the present invention can be used in the form of pharmaceuticals, cosmetics, etc., as in the conventional case, and is produced by Streptococcus thermophilus microorganisms that can be used in the production of yogurt, etc. , Can also be administered in the form of food. For example, when the hyaluronic acid obtained by the method of the present invention is used in the form of a drug or dietary supplement that appeals for effects such as beauty and anti-aging, it is a solid preparation such as a capsule, a granule, a tablet, or a powder. Alternatively, it can be orally administered as a liquid preparation such as a syrup.
以下、本発明を実施例、比較例を挙げて更に詳細に説明するが、本発明は、これらの実施例等に何ら制約されるものではない。 Hereinafter, the present invention will be described in more detail with reference to Examples and Comparative Examples, but the present invention is not limited to these Examples and the like.
実施例1〜4、比較例1〜5
(1)菌株
ストレプトコッカス・サーモフィルスYIT2084株(FERM BP−10879)
Examples 1 to 4, Comparative Examples 1 to 5
(1) Strain Streptococcus thermophilus YIT2084 strain (FERM BP-10879)
(2)前培養
表1に示すラクトース(L)−ILS培地と、炭素源をグルコース(G)又はスクロース(S)に変更したG−ILS及びS−ILS培地を用いた。炭素源を除いた成分を混合してオートクレーブした後、ろ過滅菌した炭素源を加えて調製した。
(2) Pre-culture The lactose (L) -ILS medium shown in Table 1 and the G-ILS and S-ILS media in which the carbon source was changed to glucose (G) or sucrose (S) were used. After mixing the components excluding the carbon source and autoclaving, a carbon source sterilized by filtration was added to prepare the mixture.
ストレプトコッカス・サーモフィルスYIT 2084のグリセロールストックを、2mLのL−ILS、G−ILSまたはS−ILS培地に20μL植菌し、40℃で24時間静置培養したものを第1段目の前培養液とした。第1段目の前培養液を10mLのL−ILS、G−ILSまたはS−ILS培地に100μL植菌し、同条件で24時間培養したものを第2段目の前培養液とした。 20 μL of Streptococcus thermophilus YIT 2084 glycerol stock was inoculated into 2 mL of L-ILS, G-ILS or S-ILS medium, and statically cultured at 40 ° C. for 24 hours. And said. 100 μL of the first-stage preculture solution was inoculated into 10 mL of L-ILS, G-ILS or S-ILS medium, and the mixture was cultured under the same conditions for 24 hours to prepare the second-stage preculture solution.
(3)本培養
(2)で、L−ILS、G−ILS又はS−ILS培地でそれぞれ培養した第2段目の前培養液を、50 g/Lの炭素源と、20 g/Lの酵母エキスを含む培地120mLの培地に1%植菌して培養した。なお、培養には200mL容8連式ミニジャー(Bio Jr.8、Able)を使用し、34℃、200rpm、pH6.8、通気なしの条件で行った。培養開始24時間後の培養液を用いて各種測定を行った。試験は、少なくとも2回繰り返し、その平均値を示した。
(3) In the main culture (2), the second-stage preculture solution cultured in L-ILS, G-ILS or S-ILS medium, respectively, was prepared with a 50 g / L carbon source and 20 g / L. The cells were cultured by inoculating 1% of the medium containing yeast extract in 120 mL of medium. For culturing, a 200 mL 8-series mini jar (Bio Jr. 8, Able) was used, and the culture was performed under the conditions of 34 ° C., 200 rpm, pH 6.8, and no aeration. Various measurements were performed using the culture solution 24 hours after the start of the culture. The test was repeated at least twice and the average value was shown.
(4)ヒアルロン酸の抽出・精製
培養液に終濃度が10%(w/v)になるように100%(w/v)トリクロロ酢酸を加え、4℃で2時間静置した。16,900×g、4℃で30分間遠心分離し、上清を0.45μmフィルターでろ過した後、等量の99.5%冷エタノールを加え、4℃で一晩静置した。16,900×g、4℃で30分間遠心後、沈殿物にRO水を加えて溶解し、分画分子量12,000の透析膜(Spectrum Laboratories)を用いて透析して高分子画分を得た。これをさらに分画分子量100,000の限外ろ過膜(セントリコンプラス70、Merckmillipore)で分画し、高分子画分を凍結乾燥した。
(4) Extraction / Purification of Hyaluronic Acid 100% (w / v) trichloroacetic acid was added to the culture solution so that the final concentration was 10% (w / v), and the mixture was allowed to stand at 4 ° C. for 2 hours. The mixture was centrifuged at 16,900 × g at 4 ° C. for 30 minutes, the supernatant was filtered through a 0.45 μm filter, an equal amount of 99.5% cold ethanol was added, and the mixture was allowed to stand at 4 ° C. overnight. After centrifugation at 16,900 × g at 4 ° C. for 30 minutes, RO water is added to the precipitate to dissolve it, and dialyzed using a dialysis membrane (Spectrum Laboratory) having a molecular weight cut off of 12,000 to obtain a polymer fraction. It was. This was further fractionated with an ultrafiltration membrane (Centricon Plus 70, Merckmillipore) having a molecular weight cut off of 100,000, and the polymer fraction was freeze-dried.
(5)結果
表2にヒアルロン酸の産生量を示す。また、前培養で用いる糖をスクロースに変更し、同様に本培養した場合のヒアルロン酸産生量を比較例として併せて示す。
(5) Results Table 2 shows the amount of hyaluronic acid produced. In addition, the amount of hyaluronic acid produced when the sugar used in the preculture was changed to sucrose and the main culture was performed in the same manner is also shown as a comparative example.
炭素源としてグルコース又はラクトースを前培養に用い、本培養の炭素源を変更した場合(実施例1〜4)にヒアルロン酸の産生量が向上した。特にラクトースを用いて前培養し、本培養ではグルコースを用いた場合(実施例1)にヒアルロン酸の産生量が非常に高かった。一方、前培養にスクロースを用いた場合(比較例3〜5)、ヒアルロン酸の産生量は低く、本培養で糖を変更すると産生量は著しく低下した。 When glucose or lactose was used as the carbon source for the preculture and the carbon source of the main culture was changed (Examples 1 to 4), the amount of hyaluronic acid produced was improved. In particular, when pre-cultured with lactose and glucose was used in the main culture (Example 1), the amount of hyaluronic acid produced was very high. On the other hand, when sucrose was used in the preculture (Comparative Examples 3 to 5), the amount of hyaluronic acid produced was low, and when the sugar was changed in the main culture, the amount of production decreased significantly.
(6)菌体濃度及び生産性
表2において、ヒアルロン酸産生量が特に高かった実施例1及び実施例3につき、濁度(OD660)(菌体濃度)及び菌体あたりのヒアルロン酸産生量(生産性)を測定した結果を表3、表4に示す。なお、OD660はCary 50(Agilent)を用いて測定し、菌体濃度の指標とした。
表3、4に示す通り、炭素源としてグルコース又はラクトースを前培養に用い、本培養の炭素源を変更した場合(実施例1、3)に濁度(OD660)(菌体濃度)及び菌体あたりのヒアルロン酸産生量(生産性)が向上した。一方、前培養にスクロースを用いた場合(比較例3、5)、濁度(OD660)(菌体濃度)及び菌体あたりのヒアルロン酸産生量(生産性)は低く、本培養で糖を変更すると濁度(OD660)(菌体濃度)及び菌体あたりのヒアルロン酸産生量(生産性)は著しく低下した。
(6) Cell concentration and productivity In Table 2, the turbidity (OD 660 ) (cell concentration) and the amount of hyaluronic acid produced per cell were found in Examples 1 and 3 in which the amount of hyaluronic acid produced was particularly high. The results of measuring (productivity) are shown in Tables 3 and 4. OD 660 was measured using Cary 50 (Agilent) and used as an index of mycelium concentration.
As shown in Tables 3 and 4, when glucose or lactose was used as the carbon source for the preculture and the carbon source of the main culture was changed (Examples 1 and 3), the turbidity (OD 660 ) (cell concentration) and bacteria The amount of hyaluronic acid produced per body (productivity) was improved. On the other hand, when sucrose was used for the preculture (Comparative Examples 3 and 5), the turbidity (OD 660 ) (cell concentration) and the amount of hyaluronic acid produced per cell (productivity) were low, and sugar was used in the main culture. When changed, the turbidity (OD 660 ) (cell concentration) and the amount of hyaluronic acid produced per cell (productivity) were significantly reduced.
Claims (4)
a)ストレプトコッカス・サーモフィルス属微生物を、糖類としてグルコース及びラクトースから選ばれる1種以上を含む培地で、前培養する工程、
b)前記工程で前培養した微生物を、糖類として当該前培養で用いた糖とは異なる糖を含む培地に接種し、培養する工程、
を含むヒアルロン酸の製造方法。 The following process;
a) A step of pre-culturing a Streptococcus thermophilus microorganism in a medium containing one or more selected from glucose and lactose as sugars.
b) A step of inoculating the microorganism pre-cultured in the above step into a medium containing a sugar different from the sugar used in the pre-culture as a sugar and culturing the mixture.
A method for producing hyaluronic acid, including.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019162229A JP7370196B2 (en) | 2019-09-05 | 2019-09-05 | Improved method for producing hyaluronic acid |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019162229A JP7370196B2 (en) | 2019-09-05 | 2019-09-05 | Improved method for producing hyaluronic acid |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021036841A true JP2021036841A (en) | 2021-03-11 |
JP7370196B2 JP7370196B2 (en) | 2023-10-27 |
Family
ID=74846842
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019162229A Active JP7370196B2 (en) | 2019-09-05 | 2019-09-05 | Improved method for producing hyaluronic acid |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP7370196B2 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009011315A (en) * | 2007-06-05 | 2009-01-22 | Mitsubishi Rayon Co Ltd | Production method of hyaluronic acid |
JP2009112260A (en) * | 2007-11-07 | 2009-05-28 | Yakult Honsha Co Ltd | Method for producing hyaluronic acid |
JP2012023996A (en) * | 2010-07-21 | 2012-02-09 | Kikkoman Corp | Method for producing hyaluronic acid |
JP2012130287A (en) * | 2010-12-22 | 2012-07-12 | Yakult Honsha Co Ltd | Highly hyaluronic acid-producing lactobacillus |
JP2012135248A (en) * | 2010-12-27 | 2012-07-19 | Mitsubishi Rayon Co Ltd | Method for producing lactic acid bacterium-derived polysaccharide |
CN104164379A (en) * | 2013-04-30 | 2014-11-26 | 大江生医股份有限公司 | Probiotic bacterial strain for producing hyaluronic acid and application thereof |
-
2019
- 2019-09-05 JP JP2019162229A patent/JP7370196B2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009011315A (en) * | 2007-06-05 | 2009-01-22 | Mitsubishi Rayon Co Ltd | Production method of hyaluronic acid |
JP2009112260A (en) * | 2007-11-07 | 2009-05-28 | Yakult Honsha Co Ltd | Method for producing hyaluronic acid |
JP2012023996A (en) * | 2010-07-21 | 2012-02-09 | Kikkoman Corp | Method for producing hyaluronic acid |
JP2012130287A (en) * | 2010-12-22 | 2012-07-12 | Yakult Honsha Co Ltd | Highly hyaluronic acid-producing lactobacillus |
JP2012135248A (en) * | 2010-12-27 | 2012-07-19 | Mitsubishi Rayon Co Ltd | Method for producing lactic acid bacterium-derived polysaccharide |
CN104164379A (en) * | 2013-04-30 | 2014-11-26 | 大江生医股份有限公司 | Probiotic bacterial strain for producing hyaluronic acid and application thereof |
Also Published As
Publication number | Publication date |
---|---|
JP7370196B2 (en) | 2023-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8183031B2 (en) | Composition containing β-glucan, method of producing the same and foods, drinks or skin moisturizers containing the composition | |
JP4920552B2 (en) | Method for producing hyaluronic acid | |
AU2076883A (en) | Hyaluronic acid from bacterial culture | |
JP6523579B2 (en) | Extracellular polysaccharide of lactic acid bacteria and use thereof | |
KR101413784B1 (en) | Preparation method of low molecular weight sodium hyaluronate | |
JPWO2007142285A1 (en) | Purification method of hyaluronate | |
Sakr et al. | Food wastes as natural sources of lactic acid bacterial exopolysaccharides for the functional food industry: A review | |
EP0266578A2 (en) | Method of producing hyaluronic acid | |
JP5346764B2 (en) | Production method of hyaluronic acid | |
KR101114495B1 (en) | A functional deer antlers Product produced by two-step process and method for preparing thereof | |
EP0459367B1 (en) | Method for preparing an antitumor dextran | |
JP2009060895A (en) | PRODUCTION METHOD OF SOLUBLE beta-D-GLUCAN POWDER | |
JP2021036841A (en) | Improved method for producing hyaluronic acid | |
JP2015082970A (en) | Method for producing panax ginseng effective ingredient | |
KR102249438B1 (en) | Strain for producing hyaluronic acid and preparing method of hyaluronic acid using the same | |
KR101087969B1 (en) | Method of hyaluronic acid production through fermentation process from microorganism | |
JP5479754B2 (en) | Powdered composition and tablet, and method for preventing browning of γ-aminobutyric acid and browning inhibitor | |
JPH07102100B2 (en) | Chitin degradation product food material | |
JP4944412B2 (en) | Preadipocyte differentiation inhibitor and method for producing the same | |
JP2007267720A (en) | METHOD FOR PRODUCING PURIFIED beta-1,3-1,6-D-GLUCAN | |
JP7211721B2 (en) | Novel microorganism and method for producing urolithins using said microorganism | |
JP3632197B2 (en) | Method for producing high molecular weight hyaluronic acid or salt thereof | |
JPH05103641A (en) | New food using degradation product of seaweed of brown algae | |
JP5758878B2 (en) | Purification method of hyaluronic acid | |
JP6018817B2 (en) | Fat accumulation inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220809 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230623 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230627 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230821 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231010 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231017 |
|
R151 | Written notification of patent or utility model registration |
Ref document number: 7370196 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R151 |